Cytarabine controlled-release

Drug Profile

Cytarabine controlled-release

Alternative Names: Cytarabine liposomal; Cytarabine sustained-release; DepoCyt; DepoCyte; DepoFoam Encapsulated Cytarabine; DTC 101; NS-101; Savedar

Latest Information Update: 17 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SkyePharma Inc
  • Developer IRCCS San Raffaele; Mundipharma International; Pacira Pharmaceuticals
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neoplastic meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Carcinomatous meningitis; Lymphomatous meningitis
  • No development reported B cell lymphoma; Neoplastic meningitis

Most Recent Events

  • 17 Jul 2017 No recent reports on development identified - Phase-II for B-cell lymphoma in Italy (Intrathecal)
  • 17 Jul 2017 No recent reports on development identified - Registered for Lymphomatous meningitis in South Korea (Intrathecal)
  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top